Much like the 2020 resolution, Novartis AG’s $twenty five million 2016 civil resolution with the SEC worried poor sponsorships of HCPs to conferences and incorrect payments to HCPs to gather “professional medical data.” The fact that Novartis is currently experiencing a substantially much larger—and felony—resolution for similar misconduc